THE DEAL, AT A GLANCE
From the announcementOyster Therapeutics
What it doesOyster Therapeutics aims to leverage its SELFTAC® platform to create next-generation targeted protein degraders for neurodegenerative diseases.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Who is involvedBacked by 4BIO CapitalFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗What happenedOyster Therapeutics raised Series A, announced 2026-11-10From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Why it mattersOyster Therapeutics' $60M Series A sits at the 70th percentile of tracked Unclassified rounds by size, signaling an above-median round within that database category.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Oyster Therapeutics · Financing Record
Explore source-linked visual explanations for Oyster Therapeutics. Unsupported claims are withheld while source review continues.
Record 15750 · Recorded date: 2026-11-10
Explore company records →